Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
AKBA's Cash-to-Debt is ranked higher than
70% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. AKBA: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
AKBA' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
AKBA's Interest Coverage is ranked higher than
64% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AKBA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AKBA' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -1.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE % -112.96
AKBA's ROE % is ranked lower than
80% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. AKBA: -112.96 )
Ranked among companies with meaningful ROE % only.
AKBA' s ROE % Range Over the Past 10 Years
Min: -136.35  Med: -94.01 Max: -51.66
Current: -112.96
-136.35
-51.66
ROA % -65.94
AKBA's ROA % is ranked lower than
74% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. AKBA: -65.94 )
Ranked among companies with meaningful ROA % only.
AKBA' s ROA % Range Over the Past 10 Years
Min: -365.24  Med: -61.26 Max: -47.82
Current: -65.94
-365.24
-47.82
ROC (Joel Greenblatt) % -8219.49
AKBA's ROC (Joel Greenblatt) % is ranked lower than
85% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. AKBA: -8219.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AKBA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -106220  Med: -24010.07 Max: -8219.49
Current: -8219.49
-106220
-8219.49
GuruFocus has detected 2 Warning Signs with Akebia Therapeutics Inc $AKBA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AKBA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AKBA Guru Trades in Q1 2016

Paul Tudor Jones 18,498 sh (New)
Jim Simons 28,500 sh (-73.90%)
Steven Cohen 100 sh (-99.76%)
» More
Q2 2016

AKBA Guru Trades in Q2 2016

Paul Tudor Jones 18,798 sh (+1.62%)
Steven Cohen Sold Out
Jim Simons 24,300 sh (-14.74%)
» More
Q3 2016

AKBA Guru Trades in Q3 2016

Jim Simons 151,800 sh (+524.69%)
Paul Tudor Jones 18,410 sh (-2.06%)
» More
Q4 2016

AKBA Guru Trades in Q4 2016

Jim Simons 208,600 sh (+37.42%)
Paul Tudor Jones 19,728 sh (+7.16%)
» More
» Details

Insider Trades

Latest Guru Trades with AKBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:AMEX:BTX, NAS:CCXI, NAS:ARNA, NAS:BSTC, NAS:OMED, NAS:NVAX, NAS:BOLD, NAS:FOMX, NAS:IDRA, NAS:GERN, OTCPK:PTCHF, OTCPK:DGJI, NAS:OBSV, NAS:MRUS, NAS:PDLI, NAS:SVA, OTCPK:CNBX, NAS:BLCM, NAS:AVDL, NAS:AGEN » details
Traded in other countries:AX9.Germany,
Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

Akebia Therapeutics Inc was incorporated under the laws of the state of Delaware in February 2007. The Company is a biopharmaceutical company focused on the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease. HIF is the primary regulator of the production of red blood cells, or RBCs, in the body and a potentially novel mechanism of treating anemia. Its product candidate, AKB-6548, is being developed as a once-daily oral therapy that has successfully completed a Phase 2a proof of concept study demonstrating that AKB-6548 safely and predictably raised hemoglobin levels in patients with anemia secondary to chronic kidney disease, or CKD, not requiring dialysis.

Ratios

vs
industry
vs
history
PB Ratio 5.17
AKBA's PB Ratio is ranked lower than
65% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. AKBA: 5.17 )
Ranked among companies with meaningful PB Ratio only.
AKBA' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5.37
Current: 5.17
0
5.37
Price-to-Free-Cash-Flow 6.17
AKBA's Price-to-Free-Cash-Flow is ranked higher than
88% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 24.12 vs. AKBA: 6.17 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AKBA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0  Med: 0 Max: 6.41
Current: 6.17
0
6.41
Price-to-Operating-Cash-Flow 5.89
AKBA's Price-to-Operating-Cash-Flow is ranked higher than
88% of the 232 Companies
in the Global Biotechnology industry.

( Industry Median: 20.83 vs. AKBA: 5.89 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AKBA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0  Med: 0 Max: 6.12
Current: 5.89
0
6.12
Current Ratio 2.59
AKBA's Current Ratio is ranked lower than
66% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. AKBA: 2.59 )
Ranked among companies with meaningful Current Ratio only.
AKBA' s Current Ratio Range Over the Past 10 Years
Min: 0.46  Med: 8.57 Max: 16.05
Current: 2.59
0.46
16.05
Quick Ratio 2.59
AKBA's Quick Ratio is ranked lower than
62% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. AKBA: 2.59 )
Ranked among companies with meaningful Quick Ratio only.
AKBA' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 8.57 Max: 16.05
Current: 2.59
0.46
16.05

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 12.52
AKBA's Price-to-Net-Cash is ranked lower than
71% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. AKBA: 12.52 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AKBA' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.32  Med: 3.13 Max: 14.26
Current: 12.52
2.32
14.26
Price-to-Net-Current-Asset-Value 5.51
AKBA's Price-to-Net-Current-Asset-Value is ranked higher than
53% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. AKBA: 5.51 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AKBA' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.29  Med: 3.07 Max: 6.27
Current: 5.51
2.29
6.27
Price-to-Tangible-Book 5.19
AKBA's Price-to-Tangible-Book is ranked lower than
58% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. AKBA: 5.19 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AKBA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.28  Med: 3.02 Max: 5.9
Current: 5.19
2.28
5.9
Earnings Yield (Greenblatt) % -144.56
AKBA's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. AKBA: -144.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKBA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -156.1  Med: 0 Max: No Debt
Current: -144.56
-156.1
No Debt

More Statistics

EPS (TTM) $ -3.60
Short Percentage of Float5.71%
52-Week Range $7.00 - 11.07
Shares Outstanding (Mil)38.62

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 80 85 83
EPS ($) -2.53 -2.94 -1.05
EPS without NRI ($) -2.53 -2.94 -1.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AKBA

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: BH, OPK, ARCP, RSE, AKBA Apr 01 2014 

More From Other Websites
Akebia to Present at the 16th Annual Needham Healthcare Conference Mar 29 2017
7:01 am Akebia Therapeutics announces the publication of 'positive' results from a Phase 2a study of... Mar 28 2017
Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to... Mar 28 2017
AKEBIA THERAPEUTICS, INC. Financials Mar 10 2017
Edited Transcript of AKBA earnings conference call or presentation 6-Mar-17 9:30pm GMT Mar 06 2017
Akebia Therapeutics reports 4Q loss Mar 06 2017
Akebia Therapeutics reports 4Q loss Mar 06 2017
AKEBIA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report Mar 06 2017
Akebia Announces Fourth Quarter and Full-Year 2016 Financial Results Mar 06 2017
Q4 2016 Akebia Therapeutics Inc Earnings Release - After Market Close Mar 06 2017
Akebia to Host Conference Call on March 6th to Discuss Full-Year 2016 Financial Results and... Mar 01 2017
KalVista Pharmaceuticals (KALV) in Focus: Stock Jumps 6% Feb 15 2017
The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia... Feb 14 2017
Forget Gilead, Buy These 5 Biotech Stocks Instead Feb 13 2017
Advanced Accelerator (AAAP) Catches Eye: Stock Jumps 5.4% Feb 13 2017
AKEBIA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Feb 13 2017
Akebia Licenses Portfolio of Novel HIF Compounds from Johnson & Johnson Innovation Feb 13 2017
Merrimack Pharmaceuticals employee arrested, charged with insider trading Feb 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)